Biotechnology

Spectacular advances creating a revolution in the diagnosis and treatment of male infertility

MANILA, Philippines, May 29, 2024 /PRNewswire/ -- Spectacular advances in the diagnosis and treatment of male infertility are offering new hope to the one in six couples globally who seek assisted reproduction to achieve their dreams of parenthood. A major conference on human reproduction in t...

2024-05-29 12:42 2096

US-Based Neurobiotic Leader Bened Life Launches Global Expansion with Neuralli™ MP

FREMONT, Calif., May 29, 2024 /PRNewswire/ -- Bened Life , the leader in psychobiotics, has begun worldwide expansion after finding success inthe United States with Neuralli™ MP - the first gut-brain medical probiotic for neurological conditions. Bened life is now spreadi...

2024-05-29 10:00 3439

US-Based Neurobiotic Leader Bened Life enters Japan market with Neuralli™ MP

FREMONT, Calif., May 29, 2024 /PRNewswire/ -- Bened Life , the leader in psychobiotics, has begun worldwide expansion after finding success inthe United States with Neuralli™ MP - the first gut-brain medical probiotic for neurological conditions. With investment from Teij...

2024-05-29 10:00 3347

TREEFROG THERAPEUTICS PICKS-UP BEST POSTER AWARD AT THE INTERNATIONAL SOCIETY FOR CELL & GENE THERAPY (ISCT) ANNUAL MEETING FOR THEIR CELL THERAPY PROGRAM IN PARKINSON'S DISEASE

-  Treefrog will present two posters on their cell therapy program in Parkinson's Disease and their proprietary encapsulation technology, C-Stem™ -   BORDEAUX, France, May 29, 2024 /PRNewswire/ -- TreeFrog Therapeutics  has a busy schedule at the ISCT's 30th annual meeti...

2024-05-29 06:00 2215

Metabolon Now Includes Spectral Data Files for All Global Discovery Panel Projects

MORRISVILLE, N.C., May 28, 2024 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, diagnostic, therapeutic development, and precision medicine applications, today announced the availability of spectral data fil...

2024-05-28 21:00 1826

Turn Biotechnologies Signs Global Licensing Agreement with HanAll Biopharma to Develop Eye and Ear Therapies

* Synergistic collaboration to revolutionize age-related therapies worldwide * Deal valued at over $300 million USD for initial product MOUNTAIN VIEW, Calif., May 28, 2024 /PRNewswire/ -- Turn Biotechnologies, a developer of novel mRNA medicines and enabling technologies, today announced an e...

2024-05-28 19:00 1902

Stavian Chemical Ranks 17th in ICIS Top 100, Signaling Strong Growth Amid Global Market Challenges

HANOI, Vietnam, May 28, 2024 /PRNewswire/ -- Stavian Chemical, a leading global chemical distributor headquartered inVietnam, proudly announces its exceptional performance in the prestigiousICIS Top 100 Chemical Distributors for 2024. Demonstrating the company's robust growth and resilience in th...

2024-05-28 10:00 3999

Innovent Announces Picankibart (IBI112) Achieved Primary Endpoints in a Phase 3 Clinical Trial in Treating Moderate to Severe Plaque Psoriasis, and Plans to Submit NDA to the NMPA

SAN FRANCISCO and SUZHOU, China, May 28, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major disea...

2024-05-28 08:00 3648

Telix Submits NDA for New Prostate Cancer Imaging Agent

MELBOURNE, Australia, May 27, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has submitted a New Drug Application (NDA) tothe United States (U.S.) Food and Drug Administration (FDA) for TLX007-CDx, a new and proprietary cold kit ("Kit") for th...

2024-05-27 07:21 2567

Critical need for doctors to counsel couples on potential genetic burden in offspring of older dads

MANILA, Philippines, May 26, 2024 /PRNewswire/ -- An increasing trend of older fatherhood is potentially creating a global genetic disaster with devastating health consequences for offspring. A major conference of human reproductive health in the Philippines will hear of mounting evidence that...

2024-05-26 15:59 3196

YS Biopharma Announces Name Change to LakeShore Biopharma

GAITHERSBURG, Md., May 24, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseas...

2024-05-24 19:30 2706

Menarini Group Presents Updated Data from ELECTRA and ELEVATE Combination Studies of Elacestrant (ORSERDU®) in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the ASCO 2024 Annual Meeting

* The ELECTRA and ELEVATE studies were designed to overcome different resistance mechanisms and improve patient outcomes with oral-oral combination options. * Updated results from the ELECTRA study, evaluating elacestrant in combination with abemaciclib regardless of metastatic site,show a sa...

2024-05-24 17:36 4643

CStone Announces Abstract Release of CS5001 (ROR1 ADC) First-in-Human Clinical Data on ASCO Website

* CS5001 is the first known ROR1 antibody-drug conjugate (ADC) to demonstrate clinical anti-tumor activity in both solid tumors and lymphomas, and among the top two globally in clinical development. * First-in-human study data show that CS5001 is well tolerated with promising anti-tumor activ...

2024-05-24 13:00 3282

Antengene To Present One Oral and Four Abstracts at ASCO 2024

* Oral Presentation:a Phase II study of ATG-008 (mTORC1/2 Inhibitor) combined with PD-1 antibody in patients with cervical cancer * Three Poster presentations: Phase I/II studies of ATG-031 (anti-CD24 monoclonal antibody), ATG-022 (Claudin 18.2 antibody-drug conjugate), and selinexor(XPO1 Inh...

2024-05-24 08:30 3465

Transcenta Debuts Encouraging Phase II Data from First-line Triple Combo Trial of Osemitamab (TST001) for G/GEJ Cancer at ASCO 2024

Phase II results reveal median PFS of 12.6 months in patients with CLDN18.2 high or medium expression, including in patients with PD-L1 CPS<5. PRINCETON, N.J. and SUZHOU, China, May 24, 2024 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a global clinical stage biopharm...

2024-05-24 08:00 2953

ONCOCLÍNICAS APPROVES R$ 1.5 BILLION CAPITAL INCREASE

Operation aims to strengthen the Company's financial position and maintain growth strategy SAO PAULO, May 24, 2024 /PRNewswire/ -- Oncoclínicas&Co (B3: ONCO3), a leading oncology company headquartered inLatin America, has announced that the enterprise has approved a capital increase ofR$ 1.5 bil...

2024-05-24 06:41 2824

Providence and Ontario Institute for Cancer Research (OICR) partnering to discover and develop mRNA therapeutics

CALGARY, AB and TORONTO, May 23, 2024 /PRNewswire/ -- Providence Therapeutic Holdings Inc. ("Providence"), a messenger RNA (mRNA) and lipid nanoparticle platform company engaged in the development of vaccines and therapeutics, and the Ontario Institute for Cancer Research (OICR),Ontario's largest...

2024-05-23 21:05 1762

MediThinQ Unveils SCOPEYE 3D Micro Surgery Solution; Chris Lee of VentureBlick Assumes Chairmanship

SINGAPORE, May 23, 2024 /PRNewswire/ -- MediThinQ, the Korean startup pioneering extended reality (XR) wearable displays for surgical applications, unveils its groundbreaking SCOPEYE 3D Micro Surgery Solution. This innovative microsurgery solution leverages the latest Eyes Up Display technology t...

2024-05-23 10:00 15222

Bionoxx to Highlight Innovative Strategy for Addressing Immune-Related Diseases at 2024 BIO International Conference

Corporate presentation scheduled for Tuesday, 04 June 2024 at 4:00 PM PT SAN DIEGO and SEOUL, South Korea, May 23, 2024 /PRNewswire/ -- Bionoxx Inc., an innovative biotech company developing neutrophil-directed T cell modulation technology, announced today it will unveil its novel immunomodulator...

2024-05-23 08:00 2348

Further CYP-001 GvHD Clinical Data Published in Nature Medicine

Two-year overall survival rate in patients with steroid-resistant acute GvHD was 60% MELBOURNE, Australia, May 23, 2024 /PRNewswire/ -- Cynata Therapeutics Limited (ASX: "CYP", "Cynata", or the "Company"), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to an...

2024-05-23 07:53 2639
1 ... 50515253545556 ... 186

Week's Top Stories